Pharmacologic effects on mitochondrial function

Developmental Disabilities Research Reviews

Volumn 16, Issue 2, 2010, Pages 189-199

  Cohen, Bruce H ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Drug toxicity; Free radicals; Inner mitochondrial membrane; Mitochondria; Mitochondrial DNA; Oxidative phosphorylation; POLG

Indexed keywords

ANESTHETIC AGENT; CARBOXYLIC ACID; CELL NUCLEUS DNA; MITOCHONDRIAL DNA; VALPROIC ACID;

DNA REPLICATION; ELECTROCHEMISTRY; FATTY ACID OXIDATION; GENE MUTATION; HUMAN; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TOXICITY; OXIDATIVE PHOSPHORYLATION; PATIENT SAFETY; PH MEASUREMENT; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

EID: 77956249281     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.106     Document Type: Review

References (110)

1. Aires CC, Ijlst L, Stet F, et al. 2010. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol 79:792-799.
2. Annepu J, Ravindranath V. 2000. 1-Methyl-4- phenyl-1,2,3,6- tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain. Neurosci Lett 289:209-212.
3. Avidan MS, Zhang L, Burnside BA, et al. 2008. Anesthesia awareness and the bispectral index. N Engl J Med 358:1097-1108.
4. Bailey CM, Kasiviswanathan R, Copeland WC, et al. 2009. R964C mutation of DNA polymerase gamma imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity. Antimicrob Agents Chemother 53: 2610-2612.
5. Bains R, Moe MC, Larsen GA, et al. 2006. Volatile anesthetics depolarize neural mitochondria by inhibition of the electron transport chain. Acta Anaesthesiol Scand 50:572-579.
6. Ballana E, Morales E, Rabionet R, et al. 2006. Mitochondrial 12S rRNA gene mutations affect RNA secondary structure and lead to variable penetrance in hearing impairment. Biochem Biophys Res Commun 341: 950-957.
7. Berthiaume JM, Wallace KB. 2007. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23:15-25.
8. Bicknese AR, May W, Hickey WF, et al. 1992. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann Neurol 32:767-775.
9. Bienstock RJ, Copeland WC. 2004. Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. Mitochondrion 4:203-213.
10. Bleeker-Rovers CP, Kadir SW, van Leusen R, et al. 2000. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 57:190-193.
11. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56:1405-1409.
12. Brinkman K, Kakuda TN. 2000. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis 2000; 13:5-11.
13. Burk A, Douzery EJP, Sriger MS. 2002. The secondary structure of mammalian mitochondrial 16S rRNA molecules: refinements based upon a comparative phylogenetic approach. J Mammal Evol 9:225-243.
14. Bykhovskaya Y, Mengesha E, Wang D, et al. 2004. Human mitochondrial transcription factor B1 as a modifier gene for hearing loss associated with the mitochondrial A1555G mutation. Mol Genet Metab 82:27-32. (Pubitemid 38521125)
15. Center for Drug Evaluation and Research: Guidance for Industry: Antiviral Product Development - Conducting and Submitting Virology Studies to the Agency U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) June 2006. (7070fnl.pdf available at "http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070953.pdf" www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm070953.pdf on June 1, 2010.
16. Cohen BH, Shoffner J, DeBoer G. 2010. Anesthesia and Mitochondrial Cytopathies. Available at HYPERLINK "http://www.umdf.org/atf/ cf/.../anesthesia-mitochondiral-cytopathies. pdf" www.umdf.org/atf/cf/.../ anesthesia- mitochondiral-cytopathies.pdf on June 1, 2010.
17. Cohen BH, Chinnery PF, Copeland WC. 1993. POLG-related disorders, March 16, 2010. In:Pagon RA, Bird TC, Dolan CR, Stephens K, editors. Gene reviews [Internet]. Seattle (WA): University of Washington. Available from HYPERLINK "http://www. ncbi.nlm.nih.gov/bookshelf/br.fcgi?book= gene&part= alpers"http://www.ncbi.nlm.nih. gov/bookshelf/br.fcgi?book=gene&part= alpers.
18. Combes B, Whalley PJ, Adams RH. 1972. Tetracycline and the liver. Prog Liver Dis 4: 589-596.
19. Copeland WC. 2008. Inherited mitochondrial diseases of DNA replication. Annu Rev Med 59:131-146.
20. Copeland WC. 2008. Inherited mitochondrial diseases of DNA replication. Ann Rev Med 59:309-324.
21. Cotney J, McKay SE, Shadel GS. 2009. Elucidation of separate, but collaborative functions of the rRNA methyltransferase-related human mitochondrial transcription factors B1 and B2 in mitochondrial biogenesis reveals new insight into maternally inherited deafness. Hum Mol Genet 15:2670-2682.
22. Dalakas MC. 2001. Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6:14-20.
23. DiMauro S. A history of mitochondrial diseases. J Inherit Metab Dis; DOI 10.1007/s10545-010-9082-x.
24. Du Buy HG, Showacre JL. 1961. Selective localization of tetracycline in mitochondrial of living cells. Science 133:196-197.
25. Duchen MR. 2000. Mitochondria and calcium: from cell signalling to cell death. J Physiol 529 (Pt 1):57-68.
26. Dudkina NV, Eubel H, Keegstra W, et al. 2005. Structure of a mitochondrial supercomplex formed by respiratory-chain complexes I and III. Proc Natl Acad Sci USA 102:3225-3229.
27. Dudkina NV, Kouřil R, Peters K, et al. Structure and function of mitochondrial supercomplexes. Biochim Biophys Acta. [Epub ahead of print] PubMed PMID: 20036212.
28. Dykens JA, Will Y, editors. 2008. Drug-induced mitochondrial dysfunction. Wiley: Hoboken.
29. Elliott HR, Samuels DC, Eden JA, et al. 2008. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 83:254-260.
30. Elmore SP, Quin T, Grissom SF, et al. 2001. The mitochondrial permeability transition initiates autophagy in rat hepatocytes. FASEB J 15:2286-2287.
31. Falk MJ, Kayser EB, Morgan PG, et al. 2006. Mitochondrial complex I function modulates volatile anesthetic sensitivity in C. elegans. Curr Biol 16:1641-1645.
32. Falk MJ, Rosenjack JR, Polyak E, et al. 2009. Subcomplex I lambda specifically controls integrated mitochondrial functions in Caenorhabditis elegans. PLoS One 4:e6607.
33. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, et al. 1997. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol 18: 173-178. (Pubitemid 27215295)
34. Farag E, Deboer G, Cohen BH, et al. 2005. Metabolic acidosis due to propofol infusion. Anesthesiology 102:697-698; author reply 698-699.
35. Gattermann N, Dadak M, Hofhaus G, et al. 2004. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleos Nucleot Nucleic Acids 2004; 23:1275-1279.
36. Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, et al. 2010. New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients. Food Chem Toxicol 48:1425-1438.
37. Guan MX, Yan Q, Li X, et al. 2006. Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations. Am J Hum Genet 79:291-302.
38. Hanley PJ, Ray J, Brandt U, et al. 2002. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol 544(Pt 3):687-693. (Pubitemid 35355950)
39. Henley CM, Schacht J. 1988. Pharmacokinetics of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity. Audiology 27: 137-146.
40. Hirano M, Silvestri G, Blake D, et al. 1994. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical and genetic features of an autosomal recessive mitochondrial disorder. Neurology 44: 721-727.
41. Hirano M, DiMauro S. 2001. ANT1, Twinkle, POLG, and TP: new genes open our eyes to ophthalmoplegia. Neurology 57:2163-2165. (Pubitemid 34016445)
42. Holt IJ, Harding AE, Petty RK, et al. 1990. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 46:428-433. (Pubitemid 120010945)
43. Houtkooper RH, Vaz FM. 2008. Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci 65:2493-2506.
44. Hudson G, Chinnery PF. 2006. Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet. 15:R244-R252.
45. Hutchin T. 1999. Sensorineural hearing loss and the 1555G mitochondrial DNA mutation. Acta Otolargyngol 119:48-52. (Pubitemid 29148158)
46. Kakuda TN. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685-708.
47. Kim J-S, Quin T, Lemasters JJ. 2003. Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes. Gastroenterology 124:494-503. (Pubitemid 36169265)
48. Lambert JS, Seidlin M, Reichman RC, et al. 1990. 2′,3′- Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 322:1333-1340.
49. Lefrak EA, Pitha J, Rosenheim S, et al. 1973. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314.
50. Lettéron P, Sutton A, Mansouri A, et al. 2003. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38: 133-140. (Pubitemid 36775804)
51. Lewis W, Day BJ, Copeland WC. 2003. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2:812-822.
52. Lewis W, Kohler JJ, Hosseini SH, et al. 2006. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 20:675-684.
53. Lo JC, Mulligan K, Tai VW, et al. 1997. "Buffalo hump" in men with HIV-1 infection. Lancet 351:867-870.
54. Ludke AR, Al-Shudiefat AA, Dhingra S, et al. 2009. A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Can J Physiol Pharmacol 87: 756-763.
55. Luft R, Ikkos D, Palmieri G, et al. 1962. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 41:1776-1804.
56. Lund KC, Peterson LL, Wallace KB. 2007. Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 51:2531-2539.
57. Luoma PT, Luo N, Loscher WN, et al. 2005. Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome. Hum Mol Genet 14:1907-1920. (Pubitemid 41418028)
58. McKee EE, Ferguson M, Bentley AT, et al. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50:2042-2049. (Pubitemid 43807524)
59. Machado V, Cabral A, Monteiro P, et al. 2008. Carvedilol as a protector against the cardio-toxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol 27:1277-1296.
60. Mehta R, Chan K, Lee O, et al. 2008. Drug-associated mitochondrial toxicity. In: Dykens JA, Will Y, editors. Drug-induced mitochondrial dysfunction. Wiley: Hoboken. p 71-126.
61. Moe MC, Bains R, Vinje ML, et al. Sevoflurane depolarizes pre-synaptic mitochondria in the central nervous system. Acta Anaesthesiol Scand 2004; 48:562-568. (Pubitemid 38649585)
62. Martin W, Hoffmeister M, Rotte C, et al. 2001. An overview of endosymbiotic models for the origins of eukaryotes, their ATP-producing organelles (mitochondria and hydrogenosomes), and their heterotrophic lifestyles. Biol Chem 382:1521-1539. (Pubitemid 33107694)
63. Mallon PW, Miller J, Cooper DA, et al. 2003. Prospective evaluation of the effects of anti-retroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 17:971-979.
64. Mehat R, Chan K, Lee O, et al. 2008. Drug-associated mitochondrial toxicity. In: Dykens JA, Will Y, editors. Drug-induced mitochondrial dysfunction. Wiley: Hoboken. p 71-126.
65. Morgan PG, Hoppel CL, Sedensky MM. 2002. Mitochondrial defects and anesthetic sensitivity. Anesthesiology 96:1268-1270.
66. Morgan PG, Kayser EB, Sedensky MM. 2007. C. elegans and volatile anesthetics. WormBook 3:1-11.
67. Moyle G. 2000. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22: 911-936.
68. Naviaux RK, Nguyen KV. 2004. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Ann Neurol 55:706-712.
69. Nishino I, Spinassola A, Hirano M. 1999. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283:689-692. (Pubitemid 129506238)
70. Njølstad PR, Skjeldal OH, Agsteribbe E, et al. 1997. Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity. Pediatr Neurol 16:160-162. (Pubitemid 27137456)
71. Outomuro D, Grana DR, Azzato F, et al. 2007. Adriamycin-induced myocardial toxicity: new solutions for an old problem? Int J Cardiol 117:6-15.
72. Park JS, Baek CW, Kang H, et al. 2010. Total intravenous anesthesia with propofol and remifentanil in a patient with MELAS syndrome - a case report. Kor J Anesthesiol 58: 409-412.
73. Pereira SP, Pereira GC, Moreno AJ, et al. 2009. Can drug safety be predicted and animal experiments reduced by using isolated mitochondrial fractions? Altern Lab Anim 37: 355-365.
74. Pereira CV, Moreira AC, Pereira SP, et al. 2009. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf 4:34-54.
75. Ponchaut S, van Hoof F, Veitch K. 1992. In vitro effects of valproate and valproate metabolites on mitochondrial oxidations. Relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 43:2435-2442.
76. Poulton J, Hirano M, Spinazzola A, et al. 2009. Collated mutations in mitochondrial DNA (mtDNA) depletion syndrome (excluding the mitochondrial gamma polymerase, POLG1). Biochim Biophys Acta 1792:1109-1112.
77. Prezant TR, Agapian JV, Bohlman MC, et al. 1993. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 4: 289-294.
78. Prigione A, Cortopassi G. 2007. Mitochondrial DNA deletions and chloramphenicol treatment stimulate the autophagic transcript ATG12. Autophagy 3:377-380. (Pubitemid 46986349)
79. Qi Y, Zhang Y, Wang Z, et al. 2007. Screening of common mitochondrial mutations in Chinese patients with mitochondrial encephalomyopathies. Mitochondrion 7:147-150.
80. 1- ATPase. Nature 433:773-777.
81. Ropp PA, Copeland WC. 1996. "http://www. ncbi.nlm.nih.gov/pubmed/ 8884268" Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. Genomics 36:449-458.
82. Rydzanicz M, Wróbel M, Pollak A, et al. 2010. Mutation analysis of mitochondrial 12S rRNA gene in Polish patients with non-syndromic and aminoglycoside-induced hearing loss. Biochem Biophys Res Commun 395: 116-121.
83. Saint-Marc T, Partisani M, Poizot-Martin I, et al. 1999. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13: 1659-1667.
84. Saneto RP, Lee IC, Koenig MK, et al. 2010. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure 19:140-146.
85. Schlame M. 2008. Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J Lipid Res 49:1607-1620.
86. Scott I. 2010. The role of mitochondria in mammalian antiviral defense system. Mitochondrion 10:316-320.
87. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, et al. 2010. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 31:227-285.
88. Silva MF, Ruiter JP, Illst L, et al. 1997. Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro. J Inherit Metab Dis 20:397-400.
89. Tang H-Y, Hutcheson E, Neill S, et al. 2002. Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk? Genet Med 4:336-345.
90. Van Goethem G, Dermaut B, Lofgren A, et al. 2001. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 28: 211-212. (Pubitemid 32626018)
91. Van Goethem G, Luoma P, Rantamäki M, et al. 2004. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 63:1251-1257.
92. Vasile B, Rasulo F, Candiani A, et al. 2003. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intens Care Med 29:1417-1425. (Pubitemid 37153585)
93. Venhoff N, Walker UA. 2006. Mitochondrial disease in the offspring as a result of antiretroviral therapy. Expert Opin Drug Saf 5:373-381.
94. Yang H, Liang G, Hawkins BJ, et al. 2008. Inhalational anesthetics induce cell damage by disruption of intracellular calcium homeostasis with different potencies. Anesthesiology 109:243-250.
95. Walker UA, Setzer B, Venhoff N. 2002. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16: 2165-2173. (Pubitemid 35387271)
96. Walker UA, Bäuerle J, Laguno M, et al. 2004. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 39:311-317.
97. Walker UA, Venhoff N. 2005. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 10 (Suppl 2):M117-M123. (Pubitemid 41224948)
98. Wallace DC, Singh G, Lott MT, et al. 1988. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242:1427-1430.
99. Wallace DC. 2007. Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine. Annu Rev Biochem 76:781-821
100. Wallace KB. 2007. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7:101-107.
101. Wallace KB. 2008. Mitochondrial off targets of drug therapy. Trends Pharmacol Sci 29: 361-366.
102. White AJ. 2001. Mitochondrial toxicity and HIV therapy. Sex Transm Infect 77:158-173.
103. Wong LJ, Naviaux RK, Brunetti-Pierri N, et al. 2008. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 29:E150-E172.
104. Wong LJ, Scaglia F, Graham BH, et al. 2010. Current molecular diagnostic algorithm for mitochondrial disorders. Mol Genet Metab 100:111-117.
105. Yamanaka H, Gatanaga H, Kosalaraksa P, et al. 2007. Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 195:1419-1425.
106. Yu-Wai-Man P, Chinnery PF. 1993. Leber hereditary optic neuropathy. 26 Oct 2000 [updated 10 March 2008]. In:Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington. Available from "http://www. ncbi.nlm.nih.gov/bookshelf/br.fcgi?book= gene&part=lhon"http://www.ncbi.nlm.nih. gov/bookshelf/br.fcgi?book= gene&part= lhon.
107. Zeharia A, Shaag A, Pappo O, et al. 2009. Acute infantile liver failure due to mutations in the TRMU gene. Am J Hum Genet 85:401-407.
108. Zhang Q, Raoof M, Chen Y, et al. 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107.
109. Zhou S, Heller LJ, Wallace KB. 2001. Interference with calcium-dependent mitochondrial bio-energetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 175:60-67. (Pubitemid 32783536)
110. Zimmerman HJ, Ishak KG. 1982. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2:591-597. (Pubitemid 13173942)